AZITHROMYCIN AND CO-AMOXICLAV AT DIFFERENT DOSAGES HAVE BEEN PROMOTED FOR TREATING CHILDREN WITH LOWER RESPIRATORY TRACT INFECTIONS
DOI:
https://doi.org/10.48047/dhpsth87Keywords:
Azithromycin, Co-amoxiclav, Pediatric LRTI, Antibiotic therapy and Adverse eventsAbstract
The effectiveness of azithromycin in treating acute lower respiratory tract infections (LRTI) was evaluated through a comparison study with co-amoxiclav. Depending on their weight, the children received either azithromycin (10 mg/kg/day) or co-amoxiclav (45/11.25 mg/kg/day). Co-amoxiclav treatment cured 87 percent, whereas azithromycin treatment cured 91 percent. In view of P=0.55, we conclude that there are no statistically significant differences between the two groups. The drug, however, caused significantly fewer adverse reactions in patients, most of which occurred in the gastrointestinal system. Patients who received azithromycin and co-amoxiclav between 25 and 30 days after treatment showed improvement by their third visit. The benefits of azithromycin are greater for children with LRTI than those of coamoxiclav because it is safe, effective, and convenient.
Downloads
References
Dunn, J. C. & Barradell, L. B. (1996). Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 51, 483–505.
Langtry, H. D. & Balfour, J. A. (1998). Azithromycin: a review of its use in paediatric infectious diseases. Drugs 56, 273–97.
Peters, D. H., Friedel, H. A. & McTavish, D. (1992). Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44, 750–9.
Neu, H. C. (1991). Clinical microbiology of azithromycin. American Journal of Medicine 91, Suppl. 3A, 12–18.
Lauvau, D. V. & Verbist, L. (1997). An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group. Journal of International Medical Research 25, 285–95.
Sclar, D. A., Tartaglione, T. A. & Fine, M. J. (1994). Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infectious Agents and Disease 3, 266–73.
Behre, U., Burow, H. M., Quinn, P., Cree, F. & Harrison, H. E. (1997). Efficacy of twice-daily dosing of amoxicillin/clavulanate in acute otitis media in children. Infection 25, 163–6.
Machin, D. & Campbell, M. J. (1987). Statistical Tables for the Design of Clinical Trials, p. 53. Blackwell Scientific Publications, Oxford.
Roord, J. J., Wolf, B. H. M., Goossens, M. M. H. T. & Kimpen, J. L. L. (1996). Prospective, open, randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrobial Agents and Chemotherapy 40, 2765–8.
Treadway, G. & Pontani, D. (1996). Paediatric safety of azithromycin: worldwide experience. Journal of Antimicrobial Chemotherapy 37, Suppl. C, 143–9
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
